Abstract 3670
Background
New therapies have changed melanoma treatment after 2011; however, these changes have not been studied well, especially in BRAFMut melanomas.
Methods
We studied 4197 melanoma patients who received systemic therapy in 2011-17 in the US electronic medical record database OSCER. Among these, 1687 (40%) were studied for treatments by line of therapy (LOT) and biomarkers from 2011-16.
Results
Therapies included: 64% checkpoint inhibitors (CPI), 19% BRAF/MEK inhibitors (BRAF/MEKi), 17% chemotherapy, 16% cytokines, and 1% oncolytic viral therapy. In 2011-17, overall CPI use increased from 23% to 81% (pembrolizumab 32%, nivolumab 23%, ipilimumab/nivolumab 21%) but ipilimumab use decreased to 13%. BRAF/MEKi use did not change (20-21%) but vemurafenib (2% in 2017) was replaced by dabrafenib/trametinib and cobimetinib/vemurafenib (14% and 4%). Cytokine and chemotherapy use declined (43% to 3% and 35% to 7%, respectively). During 2011-17, CPI and BRAF/MEKi were used more in LOT 1-4 (60% and 25%) than as adjuvant (30% and 2%), whereas cytokines were used as adjuvant only (64%). CPI were used most in NRASMut (85%) and less in BRAFMut, BRAFwt, or NRASwt (57-66%). In BRAFMut, CPI use was higher in stage III (62%) than IV (52%) unlike in BRAFwt (52% stage III vs. 90% stage IV). BRAFi were used in 65% of BRAFMut, more in stage IV than III (79% vs. 34%). BRAFMut and NRASMut received less adjuvant therapy than wild-type (20-22% vs. 28-31%) but more LOT (BRAFMut had 89% LOT 1, 37% LOT 2, 13% LOT 3, 5% LOT 4+). The table compares treatment changes in BRAFMut melanoma between 2011-14 and 2015-16.Table: 1280P
Treatment changes in BRAFmut melanoma between 2011-14 and 2015-16
| Therapy | 2011-14 | 2015-16 | ||||
|---|---|---|---|---|---|---|
| Adjuvant | LOT 1 | LOT 2 | Adjuvant | LOT 1 | LOT 2 | |
| BRAF/MEKi | ||||||
| Vemurafenib | 12% | 28% | 12% | 0 | 5% | 5% |
| Dabrafenib/Trametinib | 4% | 21% | 26% | 9% | 43% | 38% |
| Cobimetinib/Vemurafenib | 0 | <1% | 2% | 0 | 4% | 10% |
| Dabrafenib | 0 | 4% | 8% | 0 | 4% | 2% |
| Trametinib | 0 | 2% | 4% | 0 | 1% | 2% |
| CPI | ||||||
| Ipilimumab | 14% | 23% | 20% | 35% | 8% | 5% |
| Pembrolizumab | 1% | 7% | 11% | 7% | 13% | 21% |
| Nivolumab | 0 | 7% | 12% | 9% | 10% | 21% |
| Ipilimumab/Nivolumab | 1% | 6% | 7% | 7% | 15% | 12% |
| Cytokines | 60% | 7% | 1% | 33% | 3% | 0 |
| Chemotherapy | 2% | 4% | 7% | 0 | 3% | 0 |
Conclusions
Checkpoint inhibitors have replaced other advanced melanoma therapies, providing more treatment options to patients with BRAFMut melanoma.
Clinical trial identification
Legal entity responsible for the study
Amgen Inc.
Funding
Amgen Inc.
Editorial Acknowledgement
Disclosure
L. Raskin: Employee, Stock ownership: Amgen Inc. S. Shah, J. Buchanan, D. Cohan: Employee, Stockholder: Amgen Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract